ANB033, a Novel CD122 Antagonist in Development for the Treatment of Inflammatory and Autoimmune Diseases, Inhibited IL-15 and IL-2 Signaling in CD8+ and CD4+ T Cells In Vitro and in a Murine Model of GvHD